Rory Hachamovitch

List of Publications by Year in Descending Order

51 papers	5,408 citations	26 h-index	60 g-index
60 ext. papers	6,569 ext. citations	6.2 avg, IF	5.11 L-index

#	Paper	IF	Citations
51	Implementation of a Myocardial Perfusion Imaging Risk Algorithm to Inform Appropriate Downstream Invasive Testing and Treatment. *Circulation: Cardiovascular Imaging*, **2021**, 14, e011984	3.9	0
50	Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association. *Circulation*, **2021**, 144, e70-e91	16.7	5
49	Stress testing and noninvasive coronary imaging: What's the best test for my patient?. *Cleveland Clinic Journal of Medicine*, **2021**, 88, 502-515	2.8	0
48	Aortic Valve Calcium in Patients With Transthyretin Cardiac Amyloidosis: A Propensity-Matched Analysis. *Circulation: Cardiovascular Imaging*, **2020**, 13, e011433	3.9	1
47	Cost-Effectiveness Analysis of Stress Cardiovascular Magnetic Resonance Imaging for Stable Chest Pain Syndromes. *JACC: Cardiovascular Imaging*, **2020**, 13, 1505-1517	8.4	24
46	Infliximab for Refractory Cardiac Sarcoidosis. *American Journal of Cardiology*, **2019**, 124, 1630-1635	3	31
45	Cardiac Magnetic Resonance Stress Perfusion Imaging for Evaluation of Patients With Chest Pain. *Journal of the American College of Cardiology*, **2019**, 74, 1741-1755	15.1	82
44	A left ventricular thrombus through the lens of nuclear myocardial perfusion imaging. *European Heart Journal*, **2019**, 40, 2379	9.5	
43	Quantitative Coronary Flow Capacity for Risk Stratification and Clinical Decision Making: Is It Ready for Prime Time?. *Journal of Nuclear Medicine*, **2019**, 60, 407-409	8.9	1
42	Update in Cardiac Sarcoidosis. *Annals of the American Thoracic Society*, **2019**, 16, 1341-1350	4.7	18
41	Technetium pyrophosphate uptake in transthyretin cardiac amyloidosis: Associations with echocardiographic disease severity and outcomes. *Journal of Nuclear Cardiology*, **2018**, 25, 1247-1256	2.1	20
40	Regional Variation in Technetium Pyrophosphate Uptake in Transthyretin Cardiac Amyloidosis and Impact on Mortality. *JACC: Cardiovascular Imaging*, **2018**, 11, 234-242	8.4	47
39	Prognostic Impact of Extent, Severity, and Heterogeneity of Abnormalities on F-FDG PET Scans for Suspected Cardiac Sarcoidosis. *JACC: Cardiovascular Imaging*, **2018**, 11, 336-345	8.4	51
38	Computed Tomographic Coronary Angiography Identification of Plaque Inflammation: An Imaging Target Within Reach?. *JAMA Cardiology*, **2018**, 3, 863-864	16.2	
37	Imaging Registries and Single-Center Series. *JACC: Cardiovascular Imaging*, **2017**, 10, 276-285	8.4	3
36	Update on Treatment in Cardiac Sarcoidosis. *Current Treatment Options in Cardiovascular Medicine*, **2017**, 19, 47	2.1	4
35	Discordance between 'actual' and 'scheduled' check-in times at a heart failure clinic. *PLoS ONE*, **2017**, 12, e0187849	3.7	5

34	Ascending Aortic Dimensions in Former National Football League Athletes. *Circulation: Cardiovascular Imaging*, **2017**, 10,	3.9	22
33	Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. *Journal of the American College of Cardiology*, **2016**, 67, 2941-8	15.1	60
32	Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis. *Journal of the American Heart Association*, **2016**, 5, e002877	6	31
31	Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. *International Journal of Cardiology*, **2016**, 214, 477-81	3.2	38
30	Assessing Level of Agreement for Atherosclerotic Cardiovascular Disease Risk Categorization Between Coronary Artery Calcium Score and the American College of Cardiology/American Heart Association Cardiovascular Prevention Guidelines and the Potential Impact on Treatment Recommendations. *American Journal of Cardiology*, **2016**, 118, 1480-1485	3	4
29	Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. *Circulation*, **2015**, 131, 19-27	16.7	279
28	Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure. *Journal of the American College of Cardiology*, **2015**, 66, 659-66	15.1	83
27	Increasing Disadvantage of "Watchful Waiting" for Repairing Degenerative Mitral Valve Disease. *Annals of Thoracic Surgery*, **2015**, 99, 1992-2000	2.7	22
26	Does ischemia burden in stable coronary artery disease effectively identify revascularization candidates? Ischemia burden in stable coronary artery disease effectively identifies revascularization candidates. *Circulation: Cardiovascular Imaging*, **2015**, 8, discussion p 8	3.9	11
25	Predicting Risk Versus Predicting Potential Survival Benefit Using 123I-mIBG Imaging in Patients With Systolic Dysfunction Eligible for Implantable Cardiac Defibrillator Implantation: Analysis of Data From the Prospective ADMIRE-HF Study. *Circulation: Cardiovascular Imaging*, **2015**, 8,	3.9	14
24	Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. *Annals of Thoracic Surgery*, **2014**, 97, 610-6	2.7	489
23	Clinical decision making with myocardial perfusion imaging in patients with known or suspected coronary artery disease. *Seminars in Nuclear Medicine*, **2014**, 44, 320-9	5.4	38
22	Clinical outcomes in fulminant myocarditis requiring extracorporeal membrane oxygenation: a weighted meta-analysis of 170 patients. *Journal of Cardiac Failure*, **2014**, 20, 400-6	3.3	47
21	Comparative definitions for moderate-severe ischemia in stress nuclear, echocardiography, and magnetic resonance imaging. *JACC: Cardiovascular Imaging*, **2014**, 7, 593-604	8.4	127
20	Cardiac Imaging as a Guide for Revascularization and Medical Management of Chronic Coronary Artery Disease. *Current Cardiovascular Imaging Reports*, **2013**, 6, 379-383	0.7	
19	Patient management after noninvasive cardiac imaging results from SPARC (Study of myocardial perfusion and coronary anatomy imaging roles in coronary artery disease). *Journal of the American College of Cardiology*, **2012**, 59, 462-74	15.1	143
18	Cost-Effectiveness of Cardiac Magnetic Resonance. *Current Cardiovascular Imaging Reports*, **2012**, 5, 69-76	0.7	
17	Assessing Risk and Predicting Outcomes in Coronary Artery Disease: Physiology, Anatomy, or Biology?. *Current Cardiovascular Imaging Reports*, **2011**, 4, 180-189	0.7	1

16	Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. *European Heart Journal*, **2011**, 32, 1012-24	9.5	336
15	Prognostic implications of myocardial perfusion single-photon emission computed tomography in the elderly. *Circulation*, **2009**, 120, 2197-206	16.7	84
14	Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary?. *Journal of Nuclear Cardiology*, **2006**, 13, 768-78	2.1	118
13	The use of nuclear cardiology in clinical decision making. *Seminars in Nuclear Medicine*, **2005**, 35, 62-72	5.4	53
12	A prognostic score for prediction of cardiac mortality risk after adenosine stress myocardial perfusion scintigraphy. *Journal of the American College of Cardiology*, **2005**, 45, 722-9	15.1	80
11	Are human readers needed for prognostication from stress myocardial perfusion SPECT? Using outcomes research to validate medical technology. *Journal of Nuclear Medicine*, **2005**, 46, 194-7	8.9	1
10	Stress myocardial perfusion single-photon emission computed tomography is clinically effective and cost effective in risk stratification of patients with a high likelihood of coronary artery disease (CAD) but no known CAD. *Journal of the American College of Cardiology*, **2004**, 43, 200-8	15.1	167
9	New frontiers in risk stratification using stress myocardial perfusion single photon emission computed tomography. *Current Opinion in Cardiology*, **2003**, 18, 494-502	2.1	5
8	Determinants of risk and its temporal variation in patients with normal stress myocardial perfusion scans: what is the warranty period of a normal scan?. *Journal of the American College of Cardiology*, **2003**, 41, 1329-40	15.1	288
7	Is there a referral bias against catheterization of patients with reduced left ventricular ejection fraction? Influence of ejection fraction and inducible ischemia on post-single-photon emission computed tomography management of patients without a history of coronary artery disease. *Journal of the American College of Cardiology*, **2003**, 42, 1396-04	15.1	31
6	Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. *Circulation*, **2003**, 107, 2900-7	16.7	1095
5	Value of stress myocardial perfusion single photon emission computed tomography in patients with normal resting electrocardiograms: an evaluation of incremental prognostic value and cost-effectiveness. *Circulation*, **2002**, 105, 823-9	16.7	164
4	Sustained reduction of exercise perfusion defect extent and severity with isosorbide mononitrate (Imdur) as demonstrated by means of technetium 99m sestamibi. *Journal of Nuclear Cardiology*, **2000**, 7, 342-53	2.1	21
3	The economic consequences of available diagnostic and prognostic strategies for the evaluation of stable angina patients: an observational assessment of the value of precatheterization ischemia. Economics of Noninvasive Diagnosis (END) Multicenter Study Group. *Journal of the American College of Cardiology*, **1998**, 32, 111-9	15.1	282
2	Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential stratification for risk of cardiac death and myocardial infarction. *Circulation*, **1998**, 97, 535-43	16.7	960
1	A primer of biostatistic and economic methods for diagnostic and prognostic modeling in nuclear cardiology: Part II. *Journal of Nuclear Cardiology*, **1997**, 4, 52-60	2.1	18